1.58
전일 마감가:
$1.61
열려 있는:
$1.61
하루 거래량:
1.69M
Relative Volume:
1.71
시가총액:
$286.10M
수익:
$109.16M
순이익/손실:
$-107.78M
주가수익비율:
-1.4282
EPS:
-1.1063
순현금흐름:
$-95.45M
1주 성능:
+5.33%
1개월 성능:
-16.40%
6개월 성능:
-35.38%
1년 성능:
+180.64%
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
IPSC
Century Therapeutics Inc
|
1.58 | 286.10M | 109.16M | -107.78M | -95.45M | -1.1063 |
|
VRTX
Vertex Pharmaceuticals Inc
|
535.22 | 135.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
819.72 | 84.39B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
202.62 | 80.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
874.52 | 55.00B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-27 | 개시 | Mizuho | Outperform |
| 2026-02-25 | 개시 | TD Cowen | Buy |
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Octagon Capital Advisors2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn
Diabetic mice kept normal blood sugar until the transplant was removed. The study lasted over 11 months. - Stock Titan
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (NASDAQ:IPSC) - Seeking Alpha
Century Therapeutics rated speculative Buy on p... - Pluang
A new executive gets the right to buy 800,000 Larimar shares - Stock Titan
Form 144 Century Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Form 144 Century Therapeutics For: 25 September By Investing.com - Investing.com UK
Form 144 Century Therapeutics For: 25 September By Investing.com - Investing.com India
Russotti Gregory Disposes 2,587 Shares of Century Therapeutics (NASDAQ: IPSC) at $1.93 Each - Kalkine Media
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com South Africa
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com Australia
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com Nigeria
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com India
Century Therapeutics CTO Gregory Russotti sells $4,992 in stock - Investing.com
Century Therapeutics CTO Gregory Russotti sells $4,992 in stock By Investing.com - Investing.com UK
Century Therapeutics (IPSC) exec sale covers RSU taxes - Stock Titan
Century Therapeutics (IPSC) insider sale only covers tax withholding - Stock Titan
Century Therapeutics (IPSC) CEO holds 3,633,839 shares after tax move - Stock Titan
Century Therapeutics SVP Douglas Carr sells $3,199 in shares - Investing.com
Century Therapeutics (NASDAQ: IPSC) officer intends $4,994 sale of stock - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer lines up 1,658-share stock sale - Stock Titan
Century Therapeutics (IPSC) awards 148,000 options vesting over 3 years - Stock Titan
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - The Globe and Mail
Century Therapeutics' SVP Finance Carr Douglas Sells 254 Shares at $2.05 Each (NASDAQ: IPSC) - Kalkine Media
Century Therapeutics (NASDAQ: IPSC) Insider Russotti Gregory Sells 534 Shares, Retains 511,785 Shares - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Australia
Century Therapeutics appoints iECURE CEO Joseph Truitt to board - Bitget
Century Therapeutics Adds Joseph Truitt to Board of Directors - Minichart
Century Therapeutics CEO Brent Pfeiffenberger Withholds Shares for Tax on RSU Vesting - kalkinemedia.com
Century Therapeutics CTO Gregory Russotti Executes Automatic Sale of 534 Shares for Tax Withholding - kalkinemedia.com
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com Nigeria
Century Therapeutics SVP sells $520 in stock for tax withholding - Investing.com
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Canada
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com UK
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - TipRanks
Century Therapeutics (IPSC) CEO shares withheld for taxes on RSU vesting - Stock Titan
Tax-withholding sale trims Century Therapeutics (NASDAQ: IPSC) insider by 534 shares - Stock Titan
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com India
Century Therapeutics adds director, sets 2026 trial timelines - Stock Titan
Century Therapeutics appoints Joseph Truitt to board - Investing.com
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance UK
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com South Africa
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Century Therapeutics Inc 주식 (IPSC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Russotti Gregory | Officer |
Sep 14 '26 |
Proposed Sale |
1.93 |
2,587 |
4,994 |
0 |
| Carr Douglas | Officer |
Sep 14 '26 |
Proposed Sale |
1.93 |
1,658 |
3,201 |
0 |
| Carr Douglas | SVP Finance & Operations |
Sep 14 '26 |
Sale |
1.93 |
1,658 |
3,200 |
502,907 |
| Carr Douglas | SVP Finance & Operations |
Sep 08 '26 |
Sale |
2.05 |
254 |
521 |
504,565 |
| Russotti Gregory | See Remarks |
Sep 08 '26 |
Sale |
2.05 |
534 |
1,095 |
511,785 |
| Russotti Gregory | Officer |
Sep 08 '26 |
Proposed Sale |
2.05 |
534 |
1,094 |
0 |
| Carr Douglas | SVP Finance & Operations |
Aug 03 '26 |
Sale |
1.98 |
275 |
544 |
504,819 |
| Russotti Gregory | See Remarks |
Jun 12 '26 |
Sale |
2.23 |
2,584 |
5,767 |
512,319 |
| Carr Douglas | SVP Finance & Operations |
Jun 12 '26 |
Sale |
2.23 |
1,654 |
3,692 |
505,094 |
| Russotti Gregory | Officer |
Jun 12 '26 |
Proposed Sale |
2.23 |
2,584 |
5,768 |
0 |
자본화:
|
볼륨(24시간):